A Phase 1 Study of Pembrolizumab Immunotherapy and Cryoablation in People With Advanced Breast Cancer

Share

Full Title

Does Cryoablation Boost Immune Response Improving the Benefits of Pembrolizumab in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer?

Purpose

Researchers want to see if adding cryoablation to immunotherapy is better than immunotherapy alone for breast cancer. The people in this study have triple-negative breast cancer (TNBC) that has spread beyond its original site. The immunotherapy being studied is pembrolizumab.

Cryoablation uses extremely cold temperatures to kill cancer cells. It is given through a needle placed directly into a tumor, guided by imaging. Some of the killed cancer cells are broken into pieces that can be seen and targeted by the immune system.

Pembrolizumab boosts the power of the immune system to find and kill cancer cells. Past studies in people with different types of cancer showed that combining immunotherapy with cryoablation was effective. If you join this study, you will be randomly assigned to receive pembrolizumab alone or with cryoablation.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have locally advanced or metastatic TNBC that will be treated with pembrolizumab.
  • Have at least one tumor that can be treated with cryoablation and is at least 1.5 cm across.
  • Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Yolanda Bryce’s office at 212-639-6530.

Protocol

23-390

Phase

Phase I (phase 1)

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

Elizabeth Comen

Diseases